pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

ascentage-pharma PRESS RELEASE ARCHIVE

Nov 4, 2019

Ascentage Pharma and Henlius Form a Combination Therapy Strategic Collaboration

Jul 21, 2019

Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US

Jul 14, 2019

Ascentage Pharma announces first patient dosed in Phase I clinical trial of APG-2575 in China as the first China-made Bcl-2 Inhibitor

Jun 3, 2019

Ascentage Pharma presents new clinical data of apoptosis-targeted drug candidates APG-115 and APG-1387 at 2019 ASCO

May 22, 2019

Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers

Apr 8, 2019

Ascentage Pharma Announces Clinical Collaboration with Junshi Bioscience to Evaluate the Combination of APG-1387 and Toripalimab in Treating Cancers

Mar 25, 2019

Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting

Mar 18, 2019

Ascentage Pharma Appoints Thomas J. Knapp as Senior Vice President, General Counsel

Feb 14, 2019

Ascentage Pharma Appoints Jeff Kmetz as Chief Business Officer

Jan 8, 2019

Ascentage Pharma Announces New License with Unity Biotechnology

Jan 6, 2019

Ascentage Pharma and MD Anderson Cancer Center Announce Strategic Alliance in Cancer Drug Development

Dec 19, 2018

Ascentage Pharma Announces Strategic Collaboration with Genor Biopharma

Dec 3, 2018

Ascentage Pharma Announces Oral Presentation of Novel, Third-Generation BCR-ABL Inhibitor in Myelogenous Leukemia Patients at the 60th American Society of Hematology Annual Meeting

Nov 21, 2018

Ascentage Pharma to Present New Clinical Data at the ASH 2018 Annual Meeting

Nov 13, 2018

Ascentage Pharma Presenting New Clinical Data of Novel Dual Bcl-2/Bcl-xL Inhibitor APG-1252 at Asia Conference on Lung Cancer 2018 (ACLC)

Jul 17, 2018

Ascentage Pharma Raises $150 Million in Series C Financing

May 21, 2018

Ascentage Pharma Announces Promising Phase 1 Interim Results in Two Clinical Programs to Be Presented at 2018 ASCO Annual Meeting

Apr 12, 2018

Ascentage Pharma Announces Five Abstracts To Be Presented at the 2018 American Association for Cancer Research Annual Meeting

Feb 21, 2018

Ascentage Pharma to Present at the IASLC 18th Lung Cancer Targeted Therapies Meeting

Jan 8, 2018

Ascentage Pharma Announces Acceptance of IND Application by China FDA for Clinical Study of Novel IAP Inhibitor to Treat Hepatitis B Infection

Jan 5, 2018

Ascentage Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference

Nov 15, 2017

Ascentage Pharma Announces U.S. FDA Acceptance of IND Application for Clinical Study of Novel IAP Inhibitor APG-1387 to Treat Advanced Solid Tumors and Blood Cancers

Sep 25, 2017

Yingjie (Jason) Huang, M.D., to Join Ascentage Pharma as Senior Vice President of Clinical Development

Jul 5, 2017

Ascentage Pharma Announces Appointment of Han Li as Chief Financial Officer

Jan 9, 2017

Ascentage Pharma Announces Series B Financing of RMB 500 Million to Advance Its Apoptosis-Targeted Novel Therapeutics

Apr 24, 2016

Ascentage Pharma and UNITY Biotechnology Announce Collaboration for the Development of Senolytic Healthspan Therapies

Dec 1, 2010

Ascenta Therapeutics and Ascentage Pharma Sign R&D Collaboration and Regional License Agreements for Two Cancer Programs

Feb 11, 2010

3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics

Google Analytics Alternative